Y.S.P. Industries


Y.S.P. Industries
Concise Prescribing Info
Lidocaine HCl
Local or regional anaesth by nerve block, infiltration inj, caudal or other epidural blocks. Treatment or prophylaxis of life-threatening ventricular arrhythmias including those associated w/ MI, general anaesth in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.
Dosage/Direction for Use
Individualized dosage. Max: 3 mg/kg daily. Adult Infiltration 200 mg. Peripheral nerve blocks Paravertebral: 30-50 mg. Pudendal & paracervical: 100 mg. Sympathetic nerve blocks Cervical: 50 mg. Lumbar: 100 mg. Epidural blocks Thoracic, lumbar- & caudal-obstet analgesia, anaesth: 100-200 mg. Continuous epidural or caudal anaesth & paracervical block for obstet analgesia Max dose: Not to be repeated at <1.5 hr intervals. Adult Max: Not to exceed 200 mg. Spinal anaesth Max: Not to exceed 100 mg. Cardiac arrhythmia Adult Initially 50-100 mg at rate approx 25-50 mg/min, 2nd dose may be given after 5 min. Max: Not >200-300 mg during 1 hr period. Childn Loading dose: 0.5-1 mg/kg repeated up to 3-5 mg/kg if necessary, followed by continuous infusion of 10-50 mcg/kg/min.
Hypersensitivity to lidocaine or amide-type anaesth. Complete heart block, hypovolaemia; myasthenia gravis, severe shock or impaired cardiac conduction. Inflammation or sepsis at inj site; septicaemia. Uncorrected hypotension; coagulation disorders or use of anticoagulants; serious CNS or spinal cord diseases eg, meningitis, spinal fluid block, cranial or spinal haemorrhage, tumours, poliomyelitis, syphilis, TB or metastatic spinal cord lesions; supraventricular arrhythmia or Stokes-Adams syndrome or severe degrees of SA, AV or intraventricular block; ventricular pacemaker activity.
Special Precautions
Avoid use in patients suffering from porphyria. Interfered diagnosis of acute MI during IM inj; inadvertent inj into head & neck regions; inj into inflamed or infected areas. Myasthenia gravis, epilepsy, CHF, bradycardia or resp depression; hypovolaemia, CV impairment; hypotension; CV collapse, apnoea, convulsions, temporary blindness; persistent ocular motor dysfunction, trauma &/or local toxic effects on muscles &/or nerves. Correct hypokalaemia, hypoxia & acid-base balance disorder before treatment. Concomitant use of agents w/ availability or effects interaction eg, phenytoin. May affect ability to drive & use machines. Hepatic or renal impairment. Not to be used during pregnancy. Lactation. Not recommended for use in neonates. Monitor foetal heart rate during paracervical block. Elderly w/ compromised CV &/or hepatic function.
Adverse Reactions
Hypersensitivity reactions; dizziness or lightheadedness, nervousness, tremor, circumoral paraesthesia, tongue numbness, drowsiness, convulsions, coma; blurred vision, diplopia, transient amaurosis; tinnitus, hyperacusis; hypotension, bradycardia, myocardial depression, cardiac arrhythmias or arrest, circulatory collapse; dyspnoea, bronchospasm, resp depression & arrest; nausea, vomiting; rash, urticaria, angioedema, face oedema.
Drug Interactions
Enhanced toxicity w/ cimetidine, propranolol. Depressed microsomial activity w/ cimetidine. Reduced clearance w/ ranitidine. Increased serum levels w/ antiviral agents eg, amprenavir, atazanavir, darunavir, lopinavir. Antagonized action w/ diuretics. Additive systemic toxic effects w/ other local anaesth or drugs structurally related to amide-type local anaesth eg, antiarrhythmics (ie, mexiletine). Increased risk of ventricular arrhythmia w/ antipsychotics prolonging QT interval (eg, pimozide, sertindole, olanzapine, quetiapine, zotepine), prenylamine, adrenaline or 5-HT3 antagonists (eg, tropisetron, dolasetron); quinupristin/dalfopristin. Increased risk of enhanced & prolonged neuromuscular blockade w/ muscle relaxants eg, suxamethonium. CV collapse w/ bupivacaine in patients on treatment w/ verapamil & timolol. Reduced convulsant threshold by dopamine, 5-hydroxytryptamine; narcotics. Reduced convulsant threshold & increased CNS depressant effect by opioid-antiemetic combination. Decreased vascular absorption, increased danger of ventricular tachycardia & fibrillation w/ adrenaline. Incompatibility w/ amphotericin, methohexitone, glyceryl trinitrate. Class III anti-arrhythmics eg, amiodarone.
MIMS Class
Anaesthetics - Local & General
ATC Classification
N01BB02 - lidocaine ; Belongs to the class of amides. Used as local anesthetics.
Lycan soln for inj 2% w/v
5 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in